drugset / Trial / NCT05231733
Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of an anti-Claudin 18.2 Antibody SPX-101 in Patients with Advanced or Refractory Solid Tumors
Timeline
- Start
- 2022-05-01
- Primary completion
- 2024-04-01
- Completion
- 2024-08-01
Outcome
Outcome not reported
Stopped (Business): “Re-prioritized development strategy for this target”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SPX-101 | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | SPX-101 | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | SPX-101 | Protein / enzyme biologic | 9 mg/kg | Intravenous |
| Subject | SPX-101 | Protein / enzyme biologic | 18 mg/kg | Intravenous |
| Subject | SPX-101 | Protein / enzyme biologic | 30 mg/kg | Intravenous |